Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Non-Current Deffered Revenue (2020 - 2023)

Janux Therapeutics (JANX) has disclosed Non-Current Deffered Revenue for 4 consecutive years, with $307000.0 as the latest value for Q2 2023.

  • Quarterly Non-Current Deffered Revenue fell 94.2% to $307000.0 in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $307000.0 through Jun 2023, down 94.2% year-over-year, with the annual reading at $2.2 million for FY2022, 217.29% up from the prior year.
  • Non-Current Deffered Revenue for Q2 2023 was $307000.0 at Janux Therapeutics, down from $1.4 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $6.0 million in Q4 2020, with the low at $307000.0 in Q2 2023.
  • Average Non-Current Deffered Revenue over 4 years is $2.7 million, with a median of $2.2 million recorded in 2022.
  • The sharpest move saw Non-Current Deffered Revenue soared 217.29% in 2022, then tumbled 94.2% in 2023.
  • Over 4 years, Non-Current Deffered Revenue stood at $6.0 million in 2020, then plummeted by 88.43% to $700000.0 in 2021, then skyrocketed by 217.29% to $2.2 million in 2022, then crashed by 86.18% to $307000.0 in 2023.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $307000.0, $1.4 million, and $2.2 million for Q2 2023, Q1 2023, and Q4 2022 respectively.